Genovis and ArcticZymes Technologies enter into a collaboration agreement to accelerate growth in China

Genovis and ArcticZymes are excited to announce a collaboration to speed up penetration and growth in the Chinese market. The collaboration will create several synergies that will allow both companies to tap into the projected growth potential in China for their respective market segments. The focus of the collaboration will be on sharing Business Development resources and engaging in joint marketing activities. The joint effort will allow both companies to have a direct presence in the Chinese market with local resources.

According to Dirk Hahneiser, VP of Business Development & Marketing, ArcticZymes: “Sharing our resources will not only leverage economies of scale, increased profitability, and long-term value creation for shareholders, but also frees up resources to focus even more on our customers and their needs”.

Rikke Rytter, VP Sales & Marketing at Genovis, says, “We’re excited about the collaboration because joining forces enables both Nordic enzyme companies to leverage synergies, amplify impact, mitigate risk, and expand our respective presence in this fast-growing market”.

For more information, please contact:

Fredrik Olsson, CEO, Genovis AB, [email protected]

Børge Sørvoll, CFO, ArcticZymes Technologies, [email protected]

About ArcticZymes Technologies ASA
ArcticZymes Technologies is a Norwegian life sciences company focused on the development, manufacturing, and commercialization of novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. The company is listed on the Oslo Stock Exchange since 2005 as ArcticZymes Technologies under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre. ArcticZymes Technologies’ IP and capabilities are protected via a large portfolio of patents. For more information, please visit the website:

Genovis’ business concept is to apply its knowledge and customer driven innovation to design and provide tools for the development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes™ all over the world in innovative product formats that facilitate development and quality control of biological drugs.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (US). Genovis shares are listed on Nasdaq First North Growth Market and Erik Penser Bank is the Company’s Certified Adviser, [email protected]

< | >